Inhibition of MDR1 gene expression and enhancing cellular uptake foreffective colon cancer treatment using dual-surface-functionalized nanoparticles

Biomaterials

Volumn 48, Issue , 2015, Pages 147-160

  Xiao, Bo ^a,b   Zhang, Mingzhen ^b   Viennois, Emilie ^b,c   Zhang, Yuchen ^b   Wei, Na ^b   Baker, Mark T ^b   Jung, Yunjin ^b   Merlin, Didier ^b,c  

^a SOUTHWEST UNIVERSITY   (China)

^b GEORGIA STATE UNIVERSITY   (United States)

^c ATLANTA VA MEDICAL CENTER   (United States)

Author keywords

Chemotherapy; Colon cancer; Enhanced cellular uptake; Multidrug resistant gene 1; Nanoparticles; Surface functionalization

Indexed keywords

CELL DEATH; CHEMOTHERAPY; CHITOSAN; DISEASES; GENE EXPRESSION; MAMMALS; MEDICAL NANOTECHNOLOGY; NANOPARTICLES; ONCOLOGY; PARTICLE SIZE; TOXICITY; TUMORS;

CELLULAR UPTAKE; CELLULAR UPTAKE EFFICIENCY; COLON CANCER; DRUG RESISTANT GENES; MULTIDRUG RESISTANTS; POLY LACTIC-CO-GLYCOLIC ACID; SURFACE FUNCTIONALIZATION; SURFACE-FUNCTIONALIZED NANOPARTICLES;

DRUG DELIVERY;

CAMPTOTHECIN; CHITOSAN; MULTIDRUG RESISTANCE PROTEIN 1; POLOXAMER; POLYGLACTIN; MULTIDRUG RESISTANCE PROTEIN; NANOPARTICLE;

ANIMAL EXPERIMENT; ARTICLE; CELL TRANSPORT; COLON CANCER; CYTOTOXICITY; DEPOLYMERIZATION; DRUG EFFICACY; GENE EXPRESSION; IC50; IN VITRO STUDY; MOUSE; NONHUMAN; PARTICLE SIZE; PRIORITY JOURNAL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SCANNING ELECTRON MICROSCOPY; ZETA POTENTIAL; ANIMAL; COLONIC NEOPLASMS; GENETICS; SURFACE PROPERTY;

MUS;

ANIMALS; COLONIC NEOPLASMS; GENE EXPRESSION; IN VITRO TECHNIQUES; MICE; NANOPARTICLES; P-GLYCOPROTEIN; SURFACE PROPERTIES;

EID: 84924931849     PISSN: 01429612     EISSN: 18785905     Source Type: Journal    
DOI: 10.1016/j.biomaterials.2015.01.014     Document Type: Article

References (59)

1. Twelves C., Wong A., Nowacki M.P., Burris H., Carrato A., Cassidy J., et al. Capecitabine as adjuvant treatment for stage III colon cancer. NEngl J Med 2005, 352:2696-2704.
2. Terzic J., Grivennikov S., Karin E., Karin M. Inflammation and colon cancer. Gastroenterology 2010, 138:2101-2114. e5.
3. Haller D.G., Tabernero J., Maroun J., de Braud F., Price T., Van Cutsem E., et al. Capecitabine plus oxaliplatin compared with fluorouracil and folinic acid as adjuvant therapy for stage III colon cancer. JClin Oncol 2011, 29:1465-1471.
4. Liang X.J., Meng H., Wang Y., He H.Y., Meng J., Lu J., et al. Metallofullerene nanoparticles circumvent tumor resistance to cisplatin by reactivating endocytosis. Proc Natl Acad Sci U S A 2010, 107:7449-7454.
5. Zhang Y., Tang L., Sun L., Bao J., Song C., Huang L., et al. Anovel paclitaxel-loaded poly(epsilon-caprolactone)/Poloxamer 188 blend nanoparticle overcoming multidrug resistance for cancer treatment. Acta Biomater 2010, 6:2045-2052.
6. Yan F., Zhang C., Zheng Y., Mei L., Tang L., Song C., et al. The effect of poloxamer 188 on nanoparticle morphology, size, cancer cell uptake, and cytotoxicity. Nanomedicine 2010, 6:170-178.
7. Longley D.B., Johnston P.G. Molecular mechanisms of drug resistance. JPathol 2005, 205:275-292.
8. Shen J., Wang Q., Hu Q., Li Y., Tang G., Chu P.K. Restoration of chemosensitivity by multifunctional micelles mediated by P-gp siRNA to reverse MDR. Biomaterials 2014, 35:8621-8634.
9. Soma C.E., Dubernet C., Bentolila D., Benita S., Couvreur P. Reversion of multidrug resistance by co-encapsulation of doxorubicin and cyclosporin A in polyalkylcyanoacrylate nanoparticles. Biomaterials 2000, 21:1-7.
10. Song X.R., Cai Z., Zheng Y., He G., Cui F.Y., Gong D.Q., et al. Reversion of multidrug resistance by co-encapsulation of vincristine and verapamil in PLGA nanoparticles. Eur J Pharm Sci 2009, 37:300-305.
11. Patil Y.B., Swaminathan S.K., Sadhukha T., Ma L., Panyam J. The use of nanoparticle-mediated targeted gene silencing and drug delivery to overcome tumor drug resistance. Biomaterials 2010, 31:358-365.
12. Qian L., Zheng J., Wang K., Tang Y., Zhang X., Zhang H., et al. Cationic core-shell nanoparticles with carmustine contained within O(6)-benzylguanine shell for glioma therapy. Biomaterials 2013, 34:8968-8978.
13. Zhang X., Guo S., Fan R., Yu M., Li F., Zhu C., et al. Dual-functional liposome for tumor targeting and overcoming multidrug resistance in hepatocellular carcinoma cells. Biomaterials 2012, 33:7103-7114.
14. Batrakova E.V., Kabanov A.V. Pluronic block copolymers: evolution of drug delivery concept from inert nanocarriers to biological response modifiers. JControl Release 2008, 130:98-106.
15. Batrakova E.V., Li S., Vinogradov S.V., Alakhov V.Y., Miller D.W., Kabanov A.V. Mechanism of pluronic effect on P-glycoprotein efflux system in blood-brain barrier: contributions of energy depletion and membrane fluidization. JPharmacol Exp Ther 2001, 299:483-493.
16. Hong W., Chen D., Zhang X., Zeng J., Hu H., Zhao X., et al. Reversing multidrug resistance by intracellular delivery of Pluronic(R) P85 unimers. Biomaterials 2013, 34:9602-9614.
17. Alakhov V., Moskaleva E., Batrakova E.V., Kabanov A.V. Hypersensitization of multidrug resistant human ovarian carcinoma cells by pluronic P85 block copolymer. Bioconjug Chem 1996, 7:209-216.
18. Zhao Y., Alakhova D.Y., Kim J.O., Bronich T.K., Kabanov A.V. Asimple way to enhance Doxil(R) therapy: drug release from liposomes at the tumor site by amphiphilic block copolymer. JControl Release 2013, 168:61-69.
19. Huang S.J., Sun S.L., Feng T.H., Sung K.H., Lui W.L., Wang L.F. Folate-mediated chondroitin sulfate-Pluronic 127 nanogels as a drug carrier. Eur J Pharm Sci 2009, 38:64-73.
20. Jackson J.K., Springate C.M., Hunter W.L., Burt H.M. Neutrophil activation by plasma opsonized polymeric microspheres: inhibitory effect of pluronic F127. Biomaterials 2000, 21:1483-1491.
21. Xiao K., Li Y., Luo J., Lee Y.S., Xiao W., Gonik A.M., et al. The effect of surface charge on invivo biodistribution of PEG-oligocholic acid based micellar nanoparticles. Biomaterials 2011, 32:3435-3446.
22. Verma A., Stellacci F. Effect of surface properties on nanoparticle-cell interactions. Small 2010, 6:12-21.
23. Frohlich E. The role of surface charge in cellular uptake and cytotoxicity of medical nanoparticles. Int J Nanomed 2012, 7:5577-5591.
24. Xiao B., Wan Y., Wang X., Zha Q., Liu H., Qiu Z., et al. Synthesis and characterization of N-(2-hydroxy)propyl-3-trimethyl ammonium chitosan chloride for potential application in gene delivery. Colloids Surf B Biointerfaces 2012, 91:168-174.
25. Xiao B., Laroui H., Viennois E., Ayyadurai S., Charania M.A., Zhang Y., et al. Nanoparticles with surface antibody against CD98 and carrying CD98 small interfering RNA reduce colitis in mice. Gastroenterology 2014, 146:1289-1300. e1-19.
26. Liu W., Sun S., Cao Z., Zhang X., Yao K., Lu W.W., et al. An investigation on the physicochemical properties of chitosan/DNA polyelectrolyte complexes. Biomaterials 2005, 26:2705-2711.
27. Du J.Z., Sun T.M., Song W.J., Wu J., Wang J. Atumor-acidity-activated charge-conversional nanogel as an intelligent vehicle for promoted tumoral-cell uptake and drug delivery. Angew Chem Int Ed Engl 2010, 49:3621-3626.
28. Chung Y.I., Kim J.C., Kim Y.H., Tae G., Lee S.Y., Kim K., et al. The effect of surface functionalization of PLGA nanoparticles by heparin- or chitosan-conjugated Pluronic on tumor targeting. JControl Release 2010, 143:374-382.
29. Yang R., Shim W.S., Cui F.D., Cheng G., Han X., Jin Q.R., et al. Enhanced electrostatic interaction between chitosan-modified PLGA nanoparticle and tumor. Int J Pharm 2009, 371:142-147.
30. Kim J.Y., Choi W., Kim Y.H., Tae G., Lee S.Y., Kim K., et al. In-vivo tumor targeting of pluronic-based nano-carriers. JControl Release 2010, 147:109-117.
31. Kim J.Y., Choi W.I., Kim Y.H., Tae G. Brain-targeted delivery of protein using chitosan- and RVG peptide-conjugated, pluronic-based nano-carrier. Biomaterials 2013, 34:1170-1178.
32. Liu J., Jiang Z., Zhang S., Saltzman W.M. Poly(omega-pentadecalactone-co-butylene-co-succinate) nanoparticles as biodegradable carriers for camptothecin delivery. Biomaterials 2009, 30:5707-5719.
33. Yu D., Peng P., Dharap S.S., Wang Y., Mehlig M., Chandna P., et al. Antitumor activity of poly(ethylene glycol)-camptothecin conjugate: the inhibition of tumor growth invivo. JControl Release 2005, 110:90-102.
34. Kawano K., Watanabe M., Yamamoto T., Yokoyama M., Opanasopit P., Okano T., et al. Enhanced antitumor effect of camptothecin loaded in long-circulating polymeric micelles. JControl Release 2006, 112:329-332.
35. Dai M., Xu X., Song J., Fu S., Gou M., Luo F., et al. Preparation of camptothecin-loaded PCEC microspheres for the treatment of colorectal peritoneal carcinomatosis and tumor growth in mice. Cancer Lett 2011, 312:189-196.
36. Watanabe M., Kawano K., Toma K., Hattori Y., Matitani Y. Invivo antitumor activity of camptothecin incorporated in liposomes formulated with an artificial lipid and human serum albumin. JControl Release 2008, 127:231-238.
37. Watanabe M., Kawano K., Yokoyama M., Opanasopit P., Okano T., Maitani Y. Preparation of camptothecin-loaded polymeric micelles and evaluation of their incorporation and circulation stability. Int J Pharm 2006, 308:183-189.
38. Acharya S., Sahoo S.K. PLGA nanoparticles containing various anticancer agents and tumour delivery by EPR effect. Adv Drug Deliv Rev 2011, 63:170-183.
39. Lavertu M., Methot S., Tran-Khanh N., Bushchmann M.D. High efficiency gene transfer using chitosan/DNA nanoparticles with specific combinations of molecular weight and degree of deacetylation. Biomaterials 2006, 27:4815-4824.
40. Badawy M.E.I., Rabea E.I. Potential of the biopolymer chitosan with different molecular weights to control postharvest gray mold of tomato fruit. Postharvest Biol Technol 2009, 51:110-117.
41. Wiradharma N., Khoe U., Hauser C.A., Seow S.V., Zhang S., Yang Y.Y. Synthetic cationic amphiphilic alpha-helical peptides as antimicrobial agents. Biomaterials 2011, 32:2204-2212.
42. Huang C., Jin H., Qian Y., Qi S., Luo H., Luo Q., et al. Hybrid melittin cytolytic Peptide-driven ultrasmall lipid nanoparticles block melanoma growth invivo. ACS Nano 2013, 7:5791-5800.
43. Cohen-Sela E., Chorny M., Koroukhov N., Danenberg H.D., Golomb G. Anew double emulsion solvent diffusion technique for encapsulating hydrophilic molecules in PLGA nanoparticles. JControl Release 2009, 133:90-95.
44. Mora-Huertas C.E., Fessi H., Elaissari A. Influence of process and formulation parameters on the formation of submicron particles by solvent displacement and emulsification-diffusion methods critical comparison. Adv Colloid Interface Sci 2011, 163:90-122.
45. Chen Y.F., Rosenzweig Z. Luminescent CdSe quantum dot doped stabilized micelles. Nano Lett 2002, 2:1299-1302.
46. Mu L., Feng S.S. PLGA/TPGS nanoparticles for controlled release of paclitaxel: effects of the emulsifier and drug loading ratio. Pharm Res 2003, 20:1864-1872.
47. Hassan C.M., Peppas N.A. Structure and applications of poly(vinyl alcohol) hydrogels produced by conventional crosslinking or by freezing/thawing methods. Biopolym - Pva Hydrogels - Anion Polym Nanocompos 2000, 153:37-65.
48. Chen H., Yang W., Chen H., Liu L., Gao F., Yang X., et al. Surface modification of mitoxantrone-loaded PLGA nanospheres with chitosan. Colloids Surf B Biointerfaces 2009, 73:212-218.
49. Wang Y., Li P., Kong L. Chitosan-modified PLGA nanoparticles with versatile surface for improved drug delivery. AAPS PharmSciTech 2013, 14:585-592.
50. Smith A.M., Duan H., Mohs A.M., Nie S. Bioconjugated quantum dots for invivo molecular and cellular imaging. Adv Drug Deliv Rev 2008, 60:1226-1240.
51. Kim T.H., Ihm J.E., Choi Y.J., Nah J.W., Cho C.S. Efficient gene delivery by urocanic acid-modified chitosan. JControl Release 2003, 93:389-402.
52. Liu Y.M., Reineke T.M. Hydroxyl stereochemistry and amine number within poly(glycoamidoamine)s affect intracellular DNA delivery. JAm Chem Soc 2005, 127:3004-3015.
53. Potmesil M. Camptothecins: from bench research to hospital wards. Cancer Res 1994, 54:1431-1439.
54. Kim J.H., Kim Y.S., Park K., Lee S., Nam H.Y., Min K.H., et al. Antitumor efficacy of cisplatin-loaded glycol chitosan nanoparticles in tumor-bearing mice. JControl Release 2008, 127:41-49.
55. Wu H., Wang S., Fang H., Zan X., Zhang J., Wan Y. Chitosan-polycaprolactone copolymer microspheres for transforming growth factor-beta1 delivery. Colloids Surf B Biointerfaces 2011, 82:602-608.
56. Tomoda K., Ohkoshi T., Nakajima T., Makino K. Preparation and properties of inhalable nanocomposite particles: effects of the size, weight ratio of the primary nanoparticles in nanocomposite particles and temperature at a spray-dryer inlet upon properties of nanocomposite particles. Colloids Surf B Biointerfaces 2008, 64:70-76.
57. Menon J.U., Kona S., Wadajkar A.S., Desai F., Vadla A., Nguyen K.T. Effects of surfactants on the properties of PLGA nanoparticles. JBiomed Mater Res A 2012, 100:1998-2005.
58. Xiao B., Laroui H., Ayyadurai S., Viennois E., Charania M.A., Zhang Y., et al. Mannosylated bioreducible nanoparticle-mediated macrophage-specific TNF-alpha RNA interference for IBD therapy. Biomaterials 2013, 34:7471-7482.
59. Park G., Choi C.K., English A.E., Sparer T.E. Electrical impedance measurements predict cellular transformation. Cell Biol Int 2009, 33:429-433.